ALT Altimmune, Inc.

NASDAQ
$3.06

Altimmune, Inc. (ALT) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.3% since its last earnings release on August 12, 2026.

Altimmune Beat Consensus Estimates
Wednesday, August 12, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.14)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.17

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Altimmune, Inc.

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.